Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 103 participants.

Also called NCT01131299

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 103 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01131299
Other papers using this trial's data
  • Randomized double blind clinical trial on the effect of oral α-cyclodextrin on serum lipids Lipids in health and disease, 2016-07-12 DOI, PubMed 27405337, PMC4941029 PubMed links an erratum for this paper. Erratum: PMID 28228137 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01131299. Randomized; double masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2015-02 (actual). Results posted on 2016-10-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol
Condition
Cardiovascular Disease
Intervention (Other)
Placebo
Intervention (Drug)
Alpha cyclodextrin
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct01131299
Content hash
e72b73e21f4b951f7704a6f0a32a24e72afdd06a0887a4a8ab26b6fcea8e3099